Aska-SS Xenograft Model Overview
The Aska-SS xenograft model is derived from a human synovial sarcoma cell line, Aska-SS, which was established from a primary tumor of a patient with synovial sarcoma. Synovial sarcoma is a rare and aggressive soft tissue sarcoma that typically occurs in the limbs, often in younger adults. Despite being relatively rare, synovial sarcoma is characterized by its high metastatic potential, particularly to the lungs, and a tendency for local recurrence after surgical resection. The Aska-SS xenograft model is valuable for preclinical research into the biology of synovial sarcoma, its metastatic behavior, and therapeutic resistance. Given its aggressive nature and ability to replicate key features of synovial sarcoma, including the characteristic SS18-SSX fusion gene, the Aska-SS xenograft model is widely used to test novel therapeutic strategies, including chemotherapy, targeted therapies, and immunotherapies.
Request a Custom Quote for Aska-SS Xenograft ModelBiological and Molecular Characteristics
Aska-SS cells are characterized by their mesenchymal origin and the presence of the SS18-SSX fusion gene, a key genetic alteration commonly found in synovial sarcomas. The SS18-SSX fusion results in dysregulation of transcription factors and downstream pathways that promote tumor growth, metastasis, and resistance to apoptosis. Aska-SS cells also express markers typical of synovial sarcoma, such as cytokeratins and vimentin, and are capable of forming complex, biphasic tumors composed of both epithelial and mesenchymal components. Additionally, Aska-SS cells exhibit dysregulated signaling pathways such as PI3K/AKT, MAPK/ERK, and mTOR, which are involved in cell survival, proliferation, and metastasis. These molecular features make the Aska-SS xenograft model particularly useful for evaluating therapies targeting the SS18-SSX fusion protein and these associated pathways.
| Marker | Expression Level | Function |
|---|---|---|
| SS18-SSX Fusion | Present | Oncogene fusion driving tumorigenesis |
| Cytokeratin | High | Epithelial cell marker |
| Vimentin | High | Mesenchymal marker, involved in tumor invasion |
| PI3K/AKT pathway | Dysregulated | Promotes cell survival and proliferation |
In Vivo Model Development and Tumorigenicity
The Aska-SS xenograft model is typically established by implanting Aska-SS cells into immunocompromised mice, such as NOD/SCID or NSG mice, which lack functional T and B cells. Upon implantation, the cells form solid tumors that closely resemble human synovial sarcoma in terms of morphology, growth patterns, and metastatic behavior. These tumors exhibit high cellularity, biphasic structures (epithelial and mesenchymal), and significant vascularization, reflecting the angiogenic properties of the tumor. The Aska-SS model is particularly useful for evaluating chemotherapy agents commonly used in the treatment of soft tissue sarcomas, including doxorubicin and ifosfamide.
In addition to subcutaneous implantation, orthotopic models of Aska-SS can be established by implanting the cells into the synovial tissues or soft tissues of immunocompromised mice. This orthotopic model provides a more clinically relevant setting by mimicking the natural site of tumor growth, enabling the study of local invasion, metastasis, and the effects of treatment on the tumor microenvironment. Aska-SS xenografts are capable of metastasizing to distant organs, particularly the lungs and lymph nodes, making this model valuable for studying the metastatic behavior of synovial sarcoma and for evaluating therapies aimed at preventing or treating metastasis.
Request a Custom Quote for Aska-SS Xenograft ModelHistopathology and Immunohistochemical Profile
Histopathological examination of Aska-SS xenografts reveals the characteristic biphasic pattern of synovial sarcoma, with both epithelial and mesenchymal components present. The tumors show areas of epithelial differentiation, forming gland-like structures, as well as spindle cell areas characteristic of the mesenchymal component. Immunohistochemical staining of Aska-SS xenografts shows strong expression of epithelial markers such as cytokeratin and vimentin, confirming the mixed epithelial and mesenchymal nature of the tumor. Additionally, the presence of the SS18-SSX fusion gene can be detected by specific probes, highlighting its role in the pathogenesis of synovial sarcoma. The tumors also exhibit high levels of phosphorylated AKT, indicating activation of the PI3K/AKT pathway, which promotes cell survival and resistance to chemotherapy. CD31 staining reveals significant angiogenesis within the tumors, reflecting the importance of new blood vessel formation in supporting tumor growth.
Preclinical Applications and Drug Response
The Aska-SS xenograft model is widely used to evaluate the efficacy of various therapeutic agents for synovial sarcoma. The model is particularly valuable for testing chemotherapy agents such as doxorubicin and ifosfamide, which are commonly used in the treatment of soft tissue sarcomas, including synovial sarcoma. Given the model’s ability to develop resistance to chemotherapy over time, it is ideal for studying the mechanisms of drug resistance and for testing new agents aimed at overcoming these challenges. The Aska-SS model is also highly relevant for evaluating targeted therapies, particularly those that target the SS18-SSX fusion gene, which plays a central role in the tumor’s development and progression.
In addition to chemotherapy and targeted therapies, the Aska-SS xenograft model is increasingly used to evaluate the potential of immunotherapies, including immune checkpoint inhibitors and monoclonal antibodies targeting tumor-specific antigens. The model’s ability to replicate key features of synovial sarcoma, including its aggressive growth, biphasic tumor structure, and metastatic potential, makes it an ideal platform for studying new treatment strategies. Furthermore, the ability of Aska-SS tumors to metastasize to the lungs provides an excellent opportunity to evaluate therapies aimed at preventing or treating metastatic disease, which is a critical challenge in synovial sarcoma treatment.
Request This Model
To request the Aska-SS xenograft model for your preclinical studies, please use the form below. A customized quote and additional model specifications will be provided upon inquiry.
Request a Custom Quote for Aska-SS Xenograft Model